NCT07678151尚未招募不适用
Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial
Heart Health Research Center2 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2026年7月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 260
- 试验地点
- 2
- 主要终点
- Change in Unattended Office Systolic Blood Pressure From Baseline to Week 12
研究概览
简要总结
The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg/day) with finerenone (10 mg/day, up-titrated to 20 mg after 4 weeks) can significantly lower office systolic blood pressure in adults with obesity and stage 1 hypertension (systolic BP 140-160 mmHg) who are on up to two stable antihypertensives. The study will enroll 260 participants from community settings. Beyond blood pressure, the trial will also assess effects on diastolic pressure, cumulative BP exposure, urinary albumin-to-creatinine ratio, inflammation (hs-CRP), fasting glucose, body weight, and quality of life. Safety monitoring focuses on hyperkalemia, acute kidney injury, hypotension, and hypoglycemia. If positive, this research may offer a new, mechanism-based therapeutic strategy for the growing population with cardiometabolic risk, potentially providing better cardiovascular and kidney protection than conventional approaches.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 40 years.
- •Body mass index (BMI) ≥ 28 kg/m² or abdominal obesity, defined as meeting any of the following:
- •Waist circumference ≥ 90 cm (male) or ≥ 85 cm (female); Waist-to-hip ratio ≥ 0.9 (male) or ≥ 0.85 (female); Waist-to-height ratio ≥ 0.
- •Unattended office systolic blood pressure (SBP) ≥ 140 mmHg and < 160 mmHg during the screening period (within 1 week before randomization).
- •Currently taking no more than 2 antihypertensive agents (fixed-dose combinations are counted by the number of active ingredients).
- •No changes in the type or dose of antihypertensive medications within 4 weeks before the screening visit.
- •Provide written informed consent.
排除标准
- •Diastolic blood pressure ≥ 100 mmHg. Diagnosed diabetes mellitus or fasting plasma glucose ≥ 7.0 mmol/L. History of heart failure (any ejection fraction) or left ventricular ejection fraction < 50%.
- •Acute coronary syndrome, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) within 90 days.
- •Stroke or transient ischemic attack (TIA) within 90 days. Known secondary hypertension (e.g., bilateral renal artery stenosis >75%, aldosteronism, pheochromocytoma), except documented sleep apnea.
- •Severe hepatic dysfunction (AST/ALT > 3× upper limit of normal, or Child-Pugh class C).
- •Acute kidney injury within 6 months before screening, or eGFR < 60 mL/min/1.73 m², or kidney transplant (or planned).
- •Primary adrenal insufficiency (Addison's disease). Contraindications to any component of the study drugs (e.g., urinary tract infection within 90 days, serum potassium > 5.0 mmol/L, drug allergy).
- •Major surgery under general anesthesia within 90 days before screening, or elective surgery planned within 90 days after screening.
- •Gastrointestinal surgery or disease that, in the investigator's judgment, may affect absorption of the study drug.
- •Pregnancy, lactation, or planned pregnancy (for both male and female participants) during the study period.
- •Active malignancy. Life expectancy < 3 months. Use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampicin, carbamazepine, phenytoin) that cannot be discontinued within 7 days before Day
- •Use of mineralocorticoid receptor antagonists (e.g., finerenone, eplerenone, spironolactone), renin inhibitors, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), or SGLT-1/2 inhibitors (e.g., canagliflozin) within 8 weeks before screening or during the intervention period.
- •Use of potassium supplements, potassium-sparing diuretics (e.g., amiloride, triamterene), or potassium-binding agents within 8 weeks before screening or during the intervention period.
- •Participation in a clinical trial of empagliflozin or finerenone within 1 month before screening.
- •Current use of weight-loss medications (e.g., GLP-1 receptor agonists, GIP/GLP-1 dual agonists, GLP-1/GCGR dual agonists) or prior/planned bariatric surgery.
- •Known or suspected orthostatic hypotension or autonomic dysfunction. Any condition that, in the investigator's opinion, makes the participant unsuitable for the study.
结局指标
主要结局
Change in Unattended Office Systolic Blood Pressure From Baseline to Week 12
时间窗: Baseline (Day 1) to Week 12 (visit 5, end-of-treatment visit)
次要结局
- Change in Unattended Office Diastolic Blood Pressure From Baseline to Week 12(Baseline (Day 1) to Week 12 (visit 5))
- Change in Cumulative Blood Pressure Exposure From Baseline to Week 12(Baseline (Day 1) to Week 12 (visit 5))
- Change in Log-Transformed Urinary Albumin-to-Creatinine Ratio From Baseline to Week 12(Baseline (Day 1) to Week 12 (visit 5))
- Change in High-Sensitivity C-Reactive Protein From Baseline to Week 12(Baseline (Day 1) to Week 12 (visit 5))
- Change in Fasting Plasma Glucose From Baseline to Week 12(Baseline (Day 1) to Week 12 (visit 5))
- Change in Body Weight From Baseline to Week 12(Baseline (Day 1) to Week 12 (visit 5))
- Change in EQ-5D Quality of Life Score From Baseline to Week 12(Baseline (Day 1) to Week 12 (visit 5))
- Proportion of Participants Achieving Strict Blood Pressure Control at Week 12(Week 12 (visit 5))
- Proportion of Participants With SBP >160 mmHg or Initiation of Additional Antihypertensive Therapy Within 12 Weeks(Baseline (Day 1) through Week 12 (visit 5))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 DiabetesType 2 Diabetes MellitusHypertensionNCT07541456Dr. Zarmina Younes300
进行中（未招募）
4 期
A clinical trial to study the safety and efficacy of Efonidipine + Telmisartan in the treatment of hypertension.CTRI/2024/03/064100Zuventus Healthcare Limited200
招募中
2 期
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based TherapyNCT07336797Abdelrahman Mahmoud66
尚未招募
2/3 期
The Effectiveness of Dadimavaleha as a Supplement to Iron- Folic Acid for Managing Garbhini Pandu (Anemia in Pregnancy)CTRI/2026/02/104318DrRajendra Gode Ayurved College Hospital and Research Centre80
尚未招募
2 期
Comparing Two modes of Treatments for Depression Classical Homeopathy vs Bach Flower TherapyCTRI/2025/04/084316Vidhyadeep Homoeopathic Medical College And Research Center Anita Kim100